Julia Rotow, MD, is a physician, clinical director of the Lowe Center for Thoracic Oncology, and director of Clinical Research at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School.
Julia Rotow, MD, explores the rationale, study design, and primary endpoints of the AVANZAR trial, which investigated the combination of datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin as a first-line treatment for patients with advanced non-small cell lung cancer lacking actionable mutations, and discusses the patient population most likely to benefit from this drug combination.
Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.
Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.
Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.
Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.
Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.
Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.
Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non
Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.
Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.
